Anhydrous Enol-Oxaloacetate (AEO) on Improving Fatigue in Post-COVID-19 Survivors
NCT ID: NCT04592354
Last Updated: 2020-10-19
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
UNKNOWN
Clinical Phase
NA
Total Enrollment
40 participants
Study Classification
INTERVENTIONAL
Study Start Date
2020-10-15
Study Completion Date
2021-06-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
We will conduct a double arm, randomized, double-blinded placebo controlled trial of oxaloacetate for treatment of fatigue in women with a history of COVID-19 infection, resolution of the infection, and remaining fatigue that interfere with everyday activities, based on use of a standardized questionnaire to screen for impairment.
Participants will receive a 6-week supply of the active or placebo and will be asked to take one capsule twice a day with water and food. They will be contacted weekly for two weeks by the study coordinator to assess for any side effects or difficulty taking the medication. They will be asked to again to complete the standardized questionnaire to screen for impairment after 2 weeks, and again at the end of the study at 6 weeks. Finally, any adverse reactions and symptoms will be evaluated once again four weeks later to ensure that any symptoms that may have been present during treatment have resolved.
Participants will receive a 6-week supply of the active or placebo and will be asked to take one capsule twice a day with water and food. They will be contacted weekly for two weeks by the study coordinator to assess for any side effects or difficulty taking the medication. They will be asked to again to complete the standardized questionnaire to screen for impairment after 2 weeks, and again at the end of the study at 6 weeks. Finally, any adverse reactions and symptoms will be evaluated once again four weeks later to ensure that any symptoms that may have been present during treatment have resolved.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Spa Rehabilitation, Antioxidant and Bioenergetic Supportive Treatment of Patients With Post-Covid-19 Syndrome
NCT05178225
COVID-19 Respiratory Infection
COMPLETED
NA
Exploring the Therapeutic Effects of Creatine Supplementation for Long COVID-19
NCT06992414
Long COVID Fatigue
NOT_YET_RECRUITING
NA
Use of 1-MNA to Improve Exercise Tolerance and Fatigue in Patients After COVID-19
NCT04961476
Covid19
Fatigue Syndrome, Chronic
COMPLETED
OEA and LipiSperse Metabolic Study
NCT06840080
Healthy Volunteers - Male and Female
Pharmacokinetic Study in Healthy Volunteers
COMPLETED
PHASE4
Nutraceutical Support of Fatigue Reduction, Improved Physical, Mental & Cognitive Function and Mitochondrial Function
NCT04261881
Fatigue
COMPLETED
NA
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
We will conduct a double arm, randomized, double-blinded placebo controlled trial of oxaloacetate for treatment of fatigue in women with a history of COVID-19 infection, resolution of the infection, and remaining fatigue that interfere with everyday activities, based on use of a standardized questionnaire to screen for impairment. Women will be recruited from a variety of settings including clinics affiliated with our existing doctor base, outreach through social media and notification of community organizations that serve this patient population. The study will take place at the residences of the participants, being performed virtually after receipt of informed consent paperwork, COVID-19 positive test data, and COVID -19 negative resolution data by us, and by receipt of the test product by the participant. Efforts will be made to conduct as much of this trial virtually as possible due to the Covid-19 pandemic. Women who could potentially be pregnant will undergo pregnancy testing and determination of menopausal status, if appropriate. Participants will complete baseline questionnaires that assess fatigue and depressive symptoms.
Subsequently, the participants will receive a 6-week supply of the active or placebo and will be asked to take one capsule twice a day with water and food. They will be contacted weekly for two weeks by the study coordinator to assess for any side effects or difficulty taking the medication. They will be asked to again to complete the standardized questionnaire to screen for impairment after 2 weeks, and again at the end of the study at 6 weeks. Finally, any adverse reactions and symptoms will be evaluated once again four weeks later to ensure that any symptoms that may have been present during treatment have resolved.
Subsequently, the participants will receive a 6-week supply of the active or placebo and will be asked to take one capsule twice a day with water and food. They will be contacted weekly for two weeks by the study coordinator to assess for any side effects or difficulty taking the medication. They will be asked to again to complete the standardized questionnaire to screen for impairment after 2 weeks, and again at the end of the study at 6 weeks. Finally, any adverse reactions and symptoms will be evaluated once again four weeks later to ensure that any symptoms that may have been present during treatment have resolved.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Treatment of Fatigue After Resolution of COVID-19 Infection
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Double Blinded placebo controlled comparison study
Primary Study Purpose
TREATMENT
Blinding Strategy
QUADRUPLE
Participants
Caregivers
Investigators
Outcome Assessors
Double blinded active and placebo groups
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Oxaloacetate Therapeutic Arm
* Anhydrous Enol-Oxaloacetate
* A 500 mg oxaloacetate capsule taken by mouth twice a day
* Planned study duration is 6 weeks with an interim assessment at the end of 2 weeks and final assessment at 6 weeks
Group Type
ACTIVE_COMPARATOR
Oxaloacetate Medical Food/Dietary Supplement
Intervention Type
DIETARY_SUPPLEMENT
500 mg Anhydrous Enol-Oxaloacetate BID
Placebo Arm
* Rice Flour
* A 500 mg rice flour capsule taken by mouth twice a day
Group Type
PLACEBO_COMPARATOR
Oxaloacetate Medical Food/Dietary Supplement
Intervention Type
DIETARY_SUPPLEMENT
500 mg Anhydrous Enol-Oxaloacetate BID
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Oxaloacetate Medical Food/Dietary Supplement
500 mg Anhydrous Enol-Oxaloacetate BID
Intervention Type
DIETARY_SUPPLEMENT
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 4.1.1 Women with an initial infection diagnosis COVID-19 that has been resolved, as measured by rRT PCR, who are at least 2 months after proven viral resolution.
* 4.1.2 No evidence of active/recurrent COVID-19 or other serious chronic illness.
* 4.1.3 Have significant fatigue complaints, defined as a bimodal score of 4 or greater on the Fatigue Questionnaire.
* 4.1.4 Is geographically accessible, or can fill out forms virtually, and able to participate in a study of 6-10 weeks duration.
* 4.1.5 Age \>18 years and less than 65.
* 4.1.6 Ability to complete evaluation surveys in English.
* 4.1.7 The effects of oxaloacetate on the developing human fetus at the recommended therapeutic dose are unknown. For this reason, women of childbearing potential must agree to use adequate contraception (barrier method of birth control; IUD; abstinence) prior to study entry and for the duration of study participation. Women of any age who have had their ovaries and/or uterus removed will not be at risk for pregnancy and will not require contraception. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her study physician immediately.
* Menopausal status will be established as follows: Women who are 55 years or older and who are not menstruating will be considered postmenopausal and not at risk for pregnancy. Women who are less than 55 years old who are menstruating will be considered premenopausal and will require contraception. Women who are less than 55 years with an intact uterus and ovaries who are not menstruating and have not had a menstrual period within the past 2 years will have an FSH and estradiol measured. If the values are in postmenopausal range the woman will be considered postmenopausal and she will not be considered at risk for pregnancy.
* 4.1.8 Ability to understand and the willingness to sign a written informed consent document.
* 4.1.9 No diagnosis of Clinical Depression
* 4.1.10 Is not taking an oxaloacetate supplement.
* 4.1.2 No evidence of active/recurrent COVID-19 or other serious chronic illness.
* 4.1.3 Have significant fatigue complaints, defined as a bimodal score of 4 or greater on the Fatigue Questionnaire.
* 4.1.4 Is geographically accessible, or can fill out forms virtually, and able to participate in a study of 6-10 weeks duration.
* 4.1.5 Age \>18 years and less than 65.
* 4.1.6 Ability to complete evaluation surveys in English.
* 4.1.7 The effects of oxaloacetate on the developing human fetus at the recommended therapeutic dose are unknown. For this reason, women of childbearing potential must agree to use adequate contraception (barrier method of birth control; IUD; abstinence) prior to study entry and for the duration of study participation. Women of any age who have had their ovaries and/or uterus removed will not be at risk for pregnancy and will not require contraception. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her study physician immediately.
* Menopausal status will be established as follows: Women who are 55 years or older and who are not menstruating will be considered postmenopausal and not at risk for pregnancy. Women who are less than 55 years old who are menstruating will be considered premenopausal and will require contraception. Women who are less than 55 years with an intact uterus and ovaries who are not menstruating and have not had a menstrual period within the past 2 years will have an FSH and estradiol measured. If the values are in postmenopausal range the woman will be considered postmenopausal and she will not be considered at risk for pregnancy.
* 4.1.8 Ability to understand and the willingness to sign a written informed consent document.
* 4.1.9 No diagnosis of Clinical Depression
* 4.1.10 Is not taking an oxaloacetate supplement.
Exclusion Criteria
* 4.2.1 Has another serious or chronic medical or psychiatric condition that contributes to substantial physical or emotional disability that would detract from participating in the planned study.
* 4.2.2 Taking chronic medications that would interfere with cognitive functioning such as medications for sleep, anxiety, narcotics for pain, use of illicit medical foods or cannabis.
* 4.2.3 Participants may not be receiving any other investigational agents.
* 4.2.4 History of allergic reactions attributed to compounds of similar chemical or biologic composition to oxaloacetate.
* 4.2.5 Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection of Covid-19 or other virus, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
* 4.2.6 Pregnant or breast-feeding women are excluded from this study because the safety of oxaloacetate in this setting is unknown. A pregnancy test will be performed on all women with an intact uterus and ovaries who are not determined to be postmenopausal, as described in section 4.1.7.
* 4.2.2 Taking chronic medications that would interfere with cognitive functioning such as medications for sleep, anxiety, narcotics for pain, use of illicit medical foods or cannabis.
* 4.2.3 Participants may not be receiving any other investigational agents.
* 4.2.4 History of allergic reactions attributed to compounds of similar chemical or biologic composition to oxaloacetate.
* 4.2.5 Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection of Covid-19 or other virus, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
* 4.2.6 Pregnant or breast-feeding women are excluded from this study because the safety of oxaloacetate in this setting is unknown. A pregnancy test will be performed on all women with an intact uterus and ovaries who are not determined to be postmenopausal, as described in section 4.1.7.
Minimum Eligible Age
18 Years
Maximum Eligible Age
65 Years
Eligible Sex
FEMALE
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Terra Biological LLC
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Lisa Tully, Ph.D.
Role: PRINCIPAL_INVESTIGATOR
Energy Medicine Research Institute
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Energy Medicine research Institute
Boulder, Colorado, United States
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
United States
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Rasa S, Nora-Krukle Z, Henning N, Eliassen E, Shikova E, Harrer T, Scheibenbogen C, Murovska M, Prusty BK; European Network on ME/CFS (EUROMENE). Chronic viral infections in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). J Transl Med. 2018 Oct 1;16(1):268. doi: 10.1186/s12967-018-1644-y.
Reference Type
BACKGROUND
Lyons D, Frampton M, Naqvi S, Donohoe D, Adams G, Glynn K. Fallout from the COVID-19 pandemic - should we prepare for a tsunami of post viral depression? Ir J Psychol Med. 2020 Dec;37(4):295-300. doi: 10.1017/ipm.2020.40. Epub 2020 May 15.
Reference Type
BACKGROUND
Carfi A, Bernabei R, Landi F; Gemelli Against COVID-19 Post-Acute Care Study Group. Persistent Symptoms in Patients After Acute COVID-19. JAMA. 2020 Aug 11;324(6):603-605. doi: 10.1001/jama.2020.12603.
Reference Type
BACKGROUND
Ettman CK, Abdalla SM, Cohen GH, Sampson L, Vivier PM, Galea S. Prevalence of Depression Symptoms in US Adults Before and During the COVID-19 Pandemic. JAMA Netw Open. 2020 Sep 1;3(9):e2019686. doi: 10.1001/jamanetworkopen.2020.19686.
Reference Type
BACKGROUND
Yamamoto HA, Mohanan PV. Effect of alpha-ketoglutarate and oxaloacetate on brain mitochondrial DNA damage and seizures induced by kainic acid in mice. Toxicol Lett. 2003 Jul 20;143(2):115-22. doi: 10.1016/s0378-4274(03)00114-0.
Reference Type
BACKGROUND
Campos F, Sobrino T, Ramos-Cabrer P, Castillo J. Oxaloacetate: a novel neuroprotective for acute ischemic stroke. Int J Biochem Cell Biol. 2012 Feb;44(2):262-5. doi: 10.1016/j.biocel.2011.11.003. Epub 2011 Nov 10.
Reference Type
BACKGROUND
Ruban A, Berkutzki T, Cooper I, Mohar B, Teichberg VI. Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas. Invest New Drugs. 2012 Dec;30(6):2226-35. doi: 10.1007/s10637-012-9799-5.
Reference Type
BACKGROUND
Nagy D, Marosi M, Kis Z, Farkas T, Rakos G, Vecsei L, Teichberg VI, Toldi J. Oxaloacetate decreases the infarct size and attenuates the reduction in evoked responses after photothrombotic focal ischemia in the rat cortex. Cell Mol Neurobiol. 2009 Sep;29(6-7):827-35. doi: 10.1007/s10571-009-9364-8. Epub 2009 Mar 4.
Reference Type
BACKGROUND
Zlotnik A, Gurevich B, Tkachov S, Maoz I, Shapira Y, Teichberg VI. Brain neuroprotection by scavenging blood glutamate. Exp Neurol. 2007 Jan;203(1):213-20. doi: 10.1016/j.expneurol.2006.08.021. Epub 2006 Oct 2.
Reference Type
BACKGROUND
Nagy D, Knapp L, Marosi M, Farkas T, Kis Z, Vecsei L, Teichberg VI, Toldi J. Effects of blood glutamate scavenging on cortical evoked potentials. Cell Mol Neurobiol. 2010 Oct;30(7):1101-6. doi: 10.1007/s10571-010-9542-8. Epub 2010 Jul 6.
Reference Type
BACKGROUND
Swerdlow RH, Bothwell R, Hutfles L, Burns JM, Reed GA. Tolerability and pharmacokinetics of oxaloacetate 100 mg capsules in Alzheimer's subjects. BBA Clin. 2016 Mar 10;5:120-3. doi: 10.1016/j.bbacli.2016.03.005. eCollection 2016 Jun.
Reference Type
BACKGROUND
Vidoni ED, Choi IY, Lee P, Reed G, Zhang N, Pleen J, Mahnken JD, Clutton J, Becker A, Sherry E, Bothwell R, Anderson H, Harris RA, Brooks W, Wilkins HM, Mosconi L, Burns JM, Swerdlow RH. Safety and target engagement profile of two oxaloacetate doses in Alzheimer's patients. Alzheimers Dement. 2021 Jan;17(1):7-17. doi: 10.1002/alz.12156. Epub 2020 Jul 27.
Reference Type
BACKGROUND
Matsos A, Johnston IN. Chemotherapy-induced cognitive impairments: A systematic review of the animal literature. Neurosci Biobehav Rev. 2019 Jul;102:382-399. doi: 10.1016/j.neubiorev.2019.05.001. Epub 2019 May 4.
Reference Type
BACKGROUND
Dantzer R, Kelley KW. Twenty years of research on cytokine-induced sickness behavior. Brain Behav Immun. 2007 Feb;21(2):153-60. doi: 10.1016/j.bbi.2006.09.006. Epub 2006 Nov 7.
Reference Type
BACKGROUND
Haroon E, Miller AH, Sanacora G. Inflammation, Glutamate, and Glia: A Trio of Trouble in Mood Disorders. Neuropsychopharmacology. 2017 Jan;42(1):193-215. doi: 10.1038/npp.2016.199. Epub 2016 Sep 15.
Reference Type
BACKGROUND
Boyko M, Gruenbaum SE, Gruenbaum BF, Shapira Y, Zlotnik A. Brain to blood glutamate scavenging as a novel therapeutic modality: a review. J Neural Transm (Vienna). 2014 Aug;121(8):971-9. doi: 10.1007/s00702-014-1181-7. Epub 2014 Mar 13.
Reference Type
BACKGROUND
Missailidis D, Annesley SJ, Allan CY, Sanislav O, Lidbury BA, Lewis DP, Fisher PR. An Isolated Complex V Inefficiency and Dysregulated Mitochondrial Function in Immortalized Lymphocytes from ME/CFS Patients. Int J Mol Sci. 2020 Feb 6;21(3):1074. doi: 10.3390/ijms21031074.
Reference Type
BACKGROUND
Nilsson I, Palmer J, Apostolou E, Gottfries CG, Rizwan M, Dahle C, Rosen A. Metabolic Dysfunction in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Not Due to Anti-mitochondrial Antibodies. Front Med (Lausanne). 2020 Mar 31;7:108. doi: 10.3389/fmed.2020.00108. eCollection 2020.
Reference Type
BACKGROUND
Wilkins HM, Harris JL, Carl SM, E L, Lu J, Eva Selfridge J, Roy N, Hutfles L, Koppel S, Morris J, Burns JM, Michaelis ML, Michaelis EK, Brooks WM, Swerdlow RH. Oxaloacetate activates brain mitochondrial biogenesis, enhances the insulin pathway, reduces inflammation and stimulates neurogenesis. Hum Mol Genet. 2014 Dec 15;23(24):6528-41. doi: 10.1093/hmg/ddu371. Epub 2014 Jul 15.
Reference Type
BACKGROUND
Katz JN, Chang LC, Sangha O, Fossel AH, Bates DW. Can comorbidity be measured by questionnaire rather than medical record review? Med Care. 1996 Jan;34(1):73-84. doi: 10.1097/00005650-199601000-00006.
Reference Type
BACKGROUND
Chalder T, Berelowitz G, Pawlikowska T, Watts L, Wessely S, Wright D, Wallace EP. Development of a fatigue scale. J Psychosom Res. 1993;37(2):147-53. doi: 10.1016/0022-3999(93)90081-p.
Reference Type
BACKGROUND
Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol. 1989 Oct;46(10):1121-3. doi: 10.1001/archneur.1989.00520460115022.
Reference Type
BACKGROUND
BECK AT, WARD CH, MENDELSON M, MOCK J, ERBAUGH J. An inventory for measuring depression. Arch Gen Psychiatry. 1961 Jun;4:561-71. doi: 10.1001/archpsyc.1961.01710120031004. No abstract available.
Reference Type
BACKGROUND
Sloan JA, Loprinzi CL, Novotny PJ, Barton DL, Lavasseur BI, Windschitl H. Methodologic lessons learned from hot flash studies. J Clin Oncol. 2001 Dec 1;19(23):4280-90. doi: 10.1200/JCO.2001.19.23.4280.
Reference Type
BACKGROUND
Cash A, Kaufman DL. Oxaloacetate Treatment For Mental And Physical Fatigue In Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and Long-COVID fatigue patients: a non-randomized controlled clinical trial. J Transl Med. 2022 Jun 28;20(1):295. doi: 10.1186/s12967-022-03488-3.
Reference Type
DERIVED
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TB-AEO-2020 Post Covid Fatigue
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Radicle Energy™: A Study Assessing the Impact of Health and Wellness Products on Fatigue
NCT07026448
COMPLETED
NA
Impact of Orally Administered BPM31510 on Mitochondrial Energetics in Older Adults With Sarcopenia
NCT04999488
WITHDRAWN
EARLY_PHASE1
Coenzyme Q10 Plus NADH Supplementation in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis
NCT03186027
COMPLETED
NA
Radicle Energy 24: A Study of Health and Wellness Products on Fatigue and Related Health Outcomes
NCT06201689
COMPLETED
NA
Anti-inflammatory/Antioxidant Oral Nutrition Supplementation in COVID-19
NCT04323228
UNKNOWN
PHASE2/PHASE3
VSL#3® vs Placebo in the Treatment of Fatigue and Other Symptoms in Long Covid (DELong#3)
NCT05874089
UNKNOWN
NA
Effect of Palmitoylethanolamide on Proinflammatory Markers in Adults Recently Diagnosed With COVID-19
NCT04912921
COMPLETED
NA
Coenzyme Q10 as Treatment for Long Term COVID-19
NCT04960215
COMPLETED
PHASE2
Pre-probiotic Supplementation for Post-covid Fatigue Syndrome
NCT06013072
COMPLETED
NA
Essential Oils and Post COVID-19 Fatigue
NCT04980573
COMPLETED
NA
L-carnitine for Fatigue in COPD
NCT03008356
COMPLETED
PHASE2/PHASE3
Pre-Sleep Creatine Enhances Anaerobic Power in Recreationally Active Females
NCT06937190
RECRUITING
NA
Effects of Single Sodium Bicarbonate Supplementation on National-Level Finswimming Performance
NCT07135934
RECRUITING
NA
Radicle Energy: A Study Assessing the Impact of Health and Wellness Products on Fatigue
NCT06999655
COMPLETED
NA
Clinical Trial to Measure the Maximun HR After ReConnect ® Supplementation vs. Placebo in CFS.
NCT02063126
COMPLETED
PHASE2/PHASE3
Study to Evaluate the Effect of Nicotinamide Mononucleotide (NMN) As an Adjuvant to Standard of Care (SOC) On Fatigue Associated With COVID-19 Infection
NCT05175768
TERMINATED
NA
Chronic Fatigue Etiology and Recovery in Covid-19 Patients: the Role of Fatigability
NCT04363606
TERMINATED
NA
The Effects of Tyrosol and Creatine on Endurance, Strength, and Fatigue Resistance in Healthy Adults
NCT06883292
COMPLETED
NA
Efficacy and Safety of Ozonised Oil (HOO) in COVID-19 Patients
NCT04651387
WITHDRAWN
NA
Assessing Bioavailability of CoQ10 Supplementation in Burn Patients
NCT02251626
UNKNOWN
EARLY_PHASE1
Clinical Trial of the Seaweed Supplement Fucoidan in Survivors of Cancer
NCT06295588
RECRUITING
PHASE2
Radicle Energy™ 24_RCA: A Study Assessing the Impact of Health and Wellness Products on Fatigue and Related Health Outcomes
NCT07166523
COMPLETED
NA
Inhalation of KELEA Excellerated Water in Covid-19 Infected Individuals
NCT04490824
UNKNOWN
NA
Phase III Trial of Coenzyme Q10 in Mitochondrial Disease
NCT00432744
COMPLETED
PHASE3
Coenzyme Q10 Phase III Trial in Gulf War Illness
NCT02865460
COMPLETED
PHASE3